Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Gives Nucala Initial OK In Severe Asthma After GSK Offers Price Cut

Executive Summary

Adult patients with severe eosinophilic asthma in England and Wales look set to get a much needed treatment option following NICE's provisional backing of GlaxoSmithKline's new MAb therapy.


Related Content

Glaxo Set To File Nucala In COPD, Despite Mixed Phase III Results
GSK's Nucala Shows Promise In A Rare Systemic Vasculitis


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts